CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 129 enrolled
Drug / intervention
Combination of MK3475 with Metronomic CP +1 moredrug
Likely dose
Combination of MK3475 with Metronomic CP 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02406781
NCT02406781Phase 2Completed
CompareCT.gov

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial

Institut Bergonié·interventional·Posted Apr 2, 2015·Updated Dec 10, 2025

In Brief

A Phase 2 clinical trial evaluating Combination of MK3475 with Metronomic CP and Combination of MK3475 with Metronomic CP and G100 for Sarcoma. Completed, enrolled 129 participants across 8 sites.

Detailed Summary

This is a multicenter study assessing the efficacy of different therapeutic strategy in patients with advanced sarcomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesFrance
CollaboratorsMerck Sharp & Dohme LLC, Ministry of Health, France, Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2, 2015
Enrollment StartJun 1, 2015
Primary CompletionNov 24, 2020
Study CompletionJan 15, 2023
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 11.3 years ago

Interventions

Combination of MK3475 with Metronomic CPdrug

Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule. MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.

Combination of MK3475 with Metronomic CP and G100drug

Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule. MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8. G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase). A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.